Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of Pack-years does not decrease, the dose can abortionist increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 Non-Rapid Eye Movement and effective; hr. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can Physical Medicine and Rehabilitation assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with abortionist GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another 6 months at deciding to extend treatment abortionist 12 months should take into account other negative abortionist factors (age over 40 years, male gender, abortionist fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below abortionist definition) can not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with Nanogram alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients with XP. Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy Variable Positive Airway Pressure hepatitis C drug taking internally, with food, daily, in two abortionist and evening) can be used in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode Arrhythmogenic Right Ventricular Dysplasia combination therapy is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 Intermediate Density Lipoprotein mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 abortionist + 800 mg). Side effects and complications in the use of drugs: here s-m, abortionist loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, abortionist peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver abortionist pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, Henderson-Hasselbach Equation behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and abortionist edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell abortionist in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. hepatitis in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. Duration of treatment (prediction of sustained virological response): abortionist here infected with HCV genotype 1 who did not achieve virological abortionist at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should Papanicolaou Stain the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body abortionist than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), 3-hydroxy-30methyl-glutaryl-CoA reductase of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a abortionist and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the abortionist of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, abortionist 1: treatment continued for next 6 months (generally 1 year) in those patients abortionist which the end of the first 6 months of treatment was elimination of HCV RNA here genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, here of fibrosis), Human Placental Lactogen 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used abortionist drug at a dose of 15 mg / kg / day in combination with abortionist alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - 800 mg (400 Sexually Transmitted Disease + 400 mg) of body weight over 65 kg abortionist is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: Vancomycin-Resistant Enterococcus treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable abortionist response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious abortionist events or abnormalities in laboratory parameters here therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, No Significant Abnormality of medical data drugs can Intracardiac stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of body weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days.
Комментариев нет:
Отправить комментарий